<?xml version="1.0" encoding="UTF-8"?>
<p>The modelling data suggest the initial five‐year investment could avert an estimated 13 000 hepatitis B‐related deaths and 7000 hepatitis C‐related deaths. Moreover, a continued expansion of the treatment programme beyond 2021 has the potential to avert 672 000 hepatitis B‐infections and 60 000 deaths averted from hepatitis C‐related liver disease, which would put South Africa firmly on the path to achieve elimination by 2030 (Figure 
 <xref rid="liv14222-fig-0005" ref-type="fig">5</xref>B).
 <xref rid="liv14222-bib-0035" ref-type="ref">35</xref>
</p>
